Description du projet
De nouveaux biomarqueurs de la maladie d’Alzheimer
La maladie d’Alzheimer (MA) est une affection neurodégénérative progressive pour laquelle il n’existe ni remède ni intervention susceptibles d’en modifier le cours. La recherche et le développement de nouveaux traitements ont été entravés par le manque d’outils de diagnostic précis permettant d’identifier les premiers stades de la maladie d’Alzheimer chez un patient. Financé par le programme Actions Marie Skłodowska-Curie, le projet BBDiag entend remédier à cette limitation en identifiant des biomarqueurs de la maladie d’Alzheimer et en développant des méthodes de détection spécifiques. Le projet rassemble des experts européens du domaine qui dispenseront également une formation interdisciplinaire à des jeunes chercheurs. À terme, l’objectif est de concevoir des traitements de fond et d’améliorer la prise en charge des personnes atteintes de MA.
Objectif
Alzheimer’s disease (AD) affects more than 7 million people in Europe and this figure is expected to double every 20 years. Despite intensive efforts, no disease-modifying treatments or preventive strategies are available. The lack of specific, sensitive and minimally invasive diagnostics to identify people with early-stage AD to be included in clinical drug intervention trials is among the main reasons for many notable trial failures. The main challenges in developing the required diagnostics are identification of AD biomarkers and development of their detection techniques. The complex and interdisciplinary nature of the research underlines the need for innovative training of a new generation of researchers in the field. BBDiag responds to such a need and establishes a much-needed ETN for blood based early-AD diagnostics to address these challenges. It brings together leading academic and industrial experts from five major consortia in Europe and uses their synergies to build a triple-i research & training platform with the required multidisciplinary expertise and cutting-edge technologies. BBDiag Fellows will be trained under the Vitae Researcher Development Framework innovatively combined with the BBDiag platform for gaining interdisciplinary scientific and transferable skills as well as personal quality, creative thinking and business mind-set. The ETN has a highly innovative research programme for the discovery of AD biomarkers, development of novel biosensing techniques and point of care tools, and for technological exploitation of the diagnostics. These advances will strongly support improved care provision and development of disease-modifying treatments and preventive strategies for AD patients. More importantly, BBDiag will deliver its first generation of 13 highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.
Champ scientifique
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensors
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- engineering and technologynanotechnologynano-materialstwo-dimensional nanostructuresgraphene
- medical and health sciencesbasic medicinepathology
- medical and health scienceshealth sciencespublic healthepidemiologymodeling of diseases spread
Programme(s)
Régime de financement
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinateur
PL4 8AA Plymouth
Royaume-Uni